Drug Profile
Research programme: allergy therapies and diagnostics - ImmvaRx
Alternative Names: Allergy therapies and diagnostics research programme - ImmvaRxLatest Information Update: 08 Feb 2006
Price :
$50
*
At a glance
- Originator ImmvaRx
- Class Diagnostic agents
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypersensitivity
Most Recent Events
- 08 Feb 2006 No development reported - Preclinical for Hypersensitivity (diagnosis) in USA (unspecified route)
- 08 Feb 2006 No development reported - Preclinical for Hypersensitivity in USA (unspecified route)
- 04 Dec 2003 Preclinical trials in Hypersensitivity (diagnosis) in USA (unspecified route)